Galectin Therapeutics Inc. (GALT)

[jmh0602]

interesting last hour. looks to me like a fund decided to take a position. question - I'm wondering if patients that completed the study find out which infusion they were taking at the end of their 52 weeks. From clinical trial website: "Subjects will be offered enrollment into a subsequent separate study, an open label extension study, if there is adequate tolerability and no safety issues or signs of clinical progression that would recommend discontinuation." Seems they would have to know if in order to choose. Wondering if there could be leaks before the Dec report.